following treatment for 96 h with various concentrations (100, 300,
700, and 1,000 nM) of 16b.13–15 As shown in Figure 3 (left), a dose-
dependent decrease of TB-negative cells (viable cells) was
observed in 16b-treated HL-60 cells. The IC50 value was 952.2 nM
(95% confidence interval, 658.4−2428; R2 = 0.6679). Moreover,
the ratio of the number of TB-positive cells (dead cells) to that of
TB-negative cells in HL-60 cells at each concentration of 16b
resulted in an increase in dead cells rate in a dose-dependent
manner [Figure 3 (right)]. The detail types of cell death, such as
apoptosis, necrosis, autophagy, and so on, may become clear in
future studies. These results suggest that the 16b-induced
antiproliferative effect was derived in large part from cell death;
thus, 16b inducing cell death at 100 nano-order concentrations
might be a leading compound for the development of novel
anticancer agents.
Scheme 4. Preparation of 16
In summary, a three-component reaction involving ureas,
aldehydes, and ethyl 3-dimethylaminoacrylate using anhydrous
AlCl3 to give 6 and 7 has been developed. General, efficient and
catalytic methods for synthesis of 6 and 7 have not been reported
thus far.4,5 A synthetic novelty of our protocol is as follows: 1)
Lewis acid-mediated reaction, 2) good to high yields, 3) broad
scope as for aldehydes, and ureas. Hitherto unavailable 2-amino
derivatives 8 have been obtained by transformation of the 2-thioxo
group of 6 via the substitution reaction of 14 with amines.
Although 6 and 7 showed a weak antiproliferative effect on HL-
60 cells, related 6-methyl derivative 16b showed relatively strong
activity with 100 nano-order IC50 value.
Figure 2. Antiproliferative effect of 6, 7, and 16 in HL-60 cells.
Following treatment for 96 h with 1,000 nM ATRA, 6, 7, and 16,
respectively, the cell viability of HL-60 cells was determined by
XTT assay as described in “Supplementary Material”. Relative
cell viability was calculated as the ratio of the absorbance at 450
nm of each treatment group against those of the corresponding
untreated control group. Data are shown as the means and SD
†
(standard deviation) from three independent experiments. p <
0.01 vs. control.
Acknowledgments
This work was financially supported by JSPS KAKENHI Grant
Number 16K08335, 16K01939, and 19K05703.
Supplementary Material
Supplementary Material (synthesis and characterization of
compounds, spectroscopic data of IR, NMR, MS) associated with
the article can be found, in the online version, at doi:
******/j.tetlet. *********.
References and notes
1.
Recent reviews on synthesis and biological activities of DHPMs,
see: (a) L.H.S. Matos, F.T. Masson, L.A. Simeoni, M. Homem-de-
Mello, Eur. J. Med. Chem. 143 (2018) 1779–1789; (b) R. Kaur, S.
Chaudhary, K. Kumar, M.K. Gupta, R.K. Rawal, Eur. J. Med.
Chem. 132 (2017) 108–134; (c) H. Nagarajaiah, A. Mukhopadhyay,
J.N. Moorthy, Tetrahedron Lett. 57 (2016) 5135–5149; (d) H. Cho,
Heterocycles 87 (2013) 1441–1479; (e) Suresh, J.S. Sandhu,
ARKIVOC i (2012) 66–133; (f) J.-P. Wan, Y. Liu, Synthesis (2010)
3943–3953; (g) L.-Z. Gong, X.-H. Chen, X.-Y. Xu, Chem. Eur. J.
13 (2007) 8920–8926. (h) C.O. Kappe, A. Stadler, Org. React. 63
(2004) 1–116; (i) C.O. Kappe, Eur. J. Med. Chem. 35 (2000) 1043–
1052.
2.
For example, see: (a) S. Yu, J. Wu, H. Lan, L. Gao, H. Qian, K.
Fan, Z. Yin, Org. Lett. 22 (2020) 102–105; (b) A. Mallo-Abreu, M.
Majellaro, W. Jespers, J. Azuaje, O. Caamano, X. García-Mera, J.M.
Brea, M.I. Loza, H. Gutiérrez-de-Terán, E. Sotelo, J. Med. Chem.
62 (2019) 9315–9330; (c) M. Teleb, O.H. Rizk, F.-X. Zhang, F.R.
Fronczek, G.W. Zamponi, H. Fahmy, Bioorg. Chem. 83 (2019)
354–366; (d) T. Mao, G. Liu, H. Wu, Y. Wei, Y. Gou, J. Wang, L.
Tao, J. Am. Chem. Soc. 140 (2018) 6865–6872; (e) K.M. Bairagi,
K.N. Venugopala, P.K. Mondal, R.M. Gleiser, D. Chopra, D.
García, B. Odhav, S.K. Nayak, Chem. Biol. Drug Des. 92 (2018)
1924–1932.
3.
4.
(a) B.C. Ranu, A. Hajra, U. Jana, J. Org. Chem. 65 (2000) 6270–
6272; (b) P.P. Bruah, S. Gadhwal, D. Prajapati, J.S. Sandhu, Chem.
Lett. (2002) 1038–1039.
Figure 3. 16b induces cell death in a dose-dependent manner.
Following treatment with various concentrations of 16b for 96 h,
the cell viability of HL-60 cells was determined by TB exclusion
test as described in “Supplementary Material”. (Left) Relative cell
viability was calculated using counted TB-negative cells. (Right)
the ratio of TB-positive cells to TB-negative cells in HL-60 cells
treated with each concentration of 16b was calculated. Data are
shown as the means and SD from three independent experiments.
(a) A. Stadler, C.O. Kappe, J. Comb. Chem. 3 (2001) 624–630; (b)
J.C. Barrow, P.G. Nantermet, H.G. Selnick, K.L. Glass, K.E. Rittle,
K.F. Gilbert, T.G. Steele, C.F. Homnick, R.M. Freidinger, R.W.
Ransom, P. Kling, D. Reiss, T.P. Broten, T.W. Schorn, R.S.L.
Chang, S.S. O’Malley, T.V. Olah, J.D. Ellis, A. Barrish, K.
Kassahun, P. Leppert, D. Nagarathnam, C. Forray, J. Med. Chem.
43 (2000) 2703–2718; (c) P.A. Evans, J. Qin, J.E. Robinson, B.
Bazin, Angew. Chem. Int. Ed. 46 (2007) 7417–7419.
(a) J.-P. Wan, Y. Lin, K. Hu, Y. Liu, Beilstein J. Org. Chem. 10
(2014) 287–292; (b) S. Terentjeva, D. Muceniece, V. Lusis, Chem.
Heterocycl. Comp. 49 (2014) 1757–1769; (c) E.S. Darwish, I.A.
Abdelhamid, M.A. Nasra, F.M. Abdel-Gallil, D.H. Fleita, Helv.
5.
Furthermore, we also examined the IC50 (half maximal inhibitory
concentration) value of 16b by TB (trypan blue) exclusion test